Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C42H49N5O5 |
Molar mass | 703.884 g·mol−1 |
3D model ( JSmol) | |
| |
|
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders. [1] [2] [3] It is an azetidinone derivative, and was developed from LY-307174 as a lead compound. [4] A phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder is ongoing. [5] It is also being studied for the treatment of post-traumatic stress disorder. [6]